Germany · Delayed Price · Currency is EUR Cardiol Therapeutics Statistics
Total Valuation
FRA:CT9 has a market cap or net worth of EUR 78.46 million. The enterprise value is 71.39 million.
| Market Cap | 78.46M |
| Enterprise Value | 71.39M |
Important Dates
The last earnings date was Wednesday, November 19, 2025.
| Earnings Date | Nov 19, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 98.86M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +21.91% |
| Shares Change (QoQ) | +2.51% |
| Owned by Insiders (%) | 3.45% |
| Owned by Institutions (%) | 10.43% |
| Float | 95.43M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 13.41 |
| P/TBV Ratio | 13.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -3.35 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | -4.81 |
Financial Position
The company has a current ratio of 3.89, with a Debt / Equity ratio of 0.01.
| Current Ratio | 3.89 |
| Quick Ratio | 3.59 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -347.98% and return on invested capital (ROIC) is -223.45%.
| Return on Equity (ROE) | -347.98% |
| Return on Assets (ROA) | -148.83% |
| Return on Invested Capital (ROIC) | -223.45% |
| Return on Capital Employed (ROCE) | -375.59% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -1.18M |
| Employee Count | 18 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -41.09% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -41.09% |
| 50-Day Moving Average | 0.87 |
| 200-Day Moving Average | 0.98 |
| Relative Strength Index (RSI) | 48.62 |
| Average Volume (20 Days) | 317 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -22.20M |
| Pretax Income | -21.28M |
| Net Income | -21.28M |
| EBITDA | -22.28M |
| EBIT | -22.20M |
| Earnings Per Share (EPS) | -0.26 |
Balance Sheet
The company has 7.11 million in cash and 82,115 in debt, giving a net cash position of 7.03 million.
| Cash & Cash Equivalents | 7.11M |
| Total Debt | 82,115 |
| Net Cash | 7.03M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 5.85M |
| Book Value Per Share | 0.07 |
| Working Capital | 5.82M |
Cash Flow
In the last 12 months, operating cash flow was -14.82 million and capital expenditures -16,861, giving a free cash flow of -14.84 million.
| Operating Cash Flow | -14.82M |
| Capital Expenditures | -16,861 |
| Free Cash Flow | -14.84M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:CT9 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -21.91% |
| Shareholder Yield | -21.91% |
| Earnings Yield | -27.13% |
| FCF Yield | -18.91% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |